Background: Institutional and physician-related factors can influence the way in which physicians interpret research results. The aim of this study was to determine what physicians know about, and their opinions of, hormone treatment in breast cancer patients, and the factors comprising their medical decision-making.
Introduction
The recent worldwide review of randomised trials of adjuvant tamoxifen by the Early Breast Cancer Trialists' Collaborative Group [1] demonstrated that, for women with potentially hormone-sensitive disease (i.e., those with either a positive oestrogen-receptor-assay result or those for whom there was no information on the ER status of their original tumour) a few years of tamoxifen substantially delays recurrence and improves 10-year survival. Furthermore, among such women, five years of tamoxifen provides greater benefit than only one or two years in terms of recurrence prevention during the first decade after surgery. Moreover, age and nodal status appeared to have little or no effect on the expected benefit.
Despite the ever-expanding consensus as to the efficacy of adjuvant hormonal treatment for most women with breast cancer, there is documented evidence of a significant underuse in clinical practice, particularly in the women who stand to benefit from it, i.e., younger women and those whose original disease was confined to the breast. Institutional and physician-related factors can influence how research results are interpreted by doctors as well as the economic factors that may constrain the degree to which emerging research evidence can be implemented in routine clinical practice.
To investigate doctors' knowledge and opinions about hormone treatment in Italy and to learn about the determinants of medical decision-making, we carried out a mail survey on a sample of hospital-based physicians.
Materials and methods

Questionnaire and sampling of physicians
The survey was conducted from September 1997 to July 1998. A written questionnaire was used to ascertain doctors' preferences for adjuvant hormone treatment in breast cancer patients, and how these varied according to a woman's menopausal status, the oestrogen receptor status of the original disease and the stage of the disease 500 questionnaires sent 310 non respondents (62ft) (tumour size and axillary node involvement). Doctors were asked if they would usually use tamoxifen in 12 different clinical scenarios, deriving from the combination of the following characteristics: pre-/ postmenopausal, ER+/ER-, tumour size <2 cm/>2 cm, N+/N-. The questions relating to hormone treatment in node-positive patients were posed irrespective of tumour size. The questionnaire also asked about the duration of the treatment that the clinician would routinely use in these different scenarios. Physicians were identified from three different mailing lists: the Italian Association of Medical Oncologists (AIOM), the Italian Senology Society (SIS) and the Interdisciplinary Group for Cancer Care Evaluation (GIVIO). The latter comprises a collaborative group directly involved in the conduct of large-scale randomised trials in the field of breast cancer.
A random sample of doctors was selected from each source. The questionnaire was delivered by mail, and two additional follow-up mailings were sent to non-responders. Furthermore, a random sample of non-responders was interviewed by telephone to determine whether they were significantly different in some systematic way from the responders.
The questionnaire collected information on the age, sex and specialty of each clinician, as well as the number of breast cancer patients he or she had seen in the last 12 months.
Statistical analysis
The individual effects of factors potentially influencing preferences for hormone treatment were examined using chi-square tests in a series of univariate analyses. In pre-menopausal ER+ patients, in order to control simultaneously for the possible confounding effect of the different variables, a multiple logistical regression analysis with backward variable selection was utilised. The association between exposures and outcome is thus expressed in terms of an odds ratio together with its 95% confidence interval (95% CI). In all of the analyses, hormone treatment choice (yes/no) was considered a dependent variable. The following covariates were tested: physicians' age (<45, 45-49, ^50 years), sex, specialty (oncology, surgery, radiotherapy, other), number of breast cancer patients seen in the last year ($70, 71-299, >300), affiliation (AIOM, SIS, GIVIO).
Results
Response rates
Five hundred physicians were identified, of whom one hudred ninety (38%) returned the questionnaire. Among non-responders, a random sample of 25% (77 doctors) was interviewed by phone, of whom 60 (78%) provided responses. (30) 104 (42) 30 (12) 62 (25) 19 (8) 7 (3) 5 (2) 6 (2) 17 (7) 58 (23) 135 (54) 57 (23) 83 (33) 83 (33) 83 (33) Abbreviations: AIOM -Italian Association of Medical Oncologists; SIS -Italian Senology Society; GIVIO -Interdisciplinary Group for Cancer Care Evaluation.
More than one-third of the doctors interviewed by phone (38%) did not see breast cancer patients. Therefore, the total number of available questionnaires was 250 (50%), of which 65 were from physicians who do not see patients with breast cancer (Figure 1 ).
All of the analyses are thus based on a sample of 185 physicians. Respondents' characteristics are reported in Table 1 .
Patterns of hormone treatment preference
The proportion of physicians who would routinely use tamoxifen varied markedly according to patient characteristics ( Figure 2 ). While the vast majority of doctors agreed that hormone treatment was appropriate for older women with oestrogen receptor-positive disease, roughly half of them routinely used such treatment in pre-menopausal ER+ patients. This was particularly true for women with node-negative disease, even if they were oestrogen receptor-positive.
Oestrogen receptor status was influential in determining whether or not tamoxifen was used, but this varied according to a woman's age at diagnosis. About three-quarters of the doctors would prescribe tamoxifen in an ER+ older woman, but only 2/5 would do so in an otherwise similar younger woman.
The percentage of doctors who usually recommended tamoxifen in ER-patients was very low for pre-menopausal women, while 30% to 40% prescribed it for postmenopausal patients (Figure 2 ). The vast majority of physicians considered five years as standard for women with ER+ tumours. Nevertheless, about one-quarter of the doctors chose a shorter treatment duration for node-negative, pre-menopausal patients ( Figure 3 ) and a minority of physicians routinely used tamoxifen for much longer than five years.
This pattern of treatment duration was similar for women whose original disease was ER-negative (data not shown).
The preference for hormone therapy seemed to be influenced by a doctor's age, with older clinicians being less likely to prescribe tamoxifen, particularly in lowrisk patients (Table 2 and Figure 4) . Similarly, a significantly lower proportion of physicians seeing more than 300 breast cancer patients in a year tended to prescribe tamoxifen to pre-menopausal, low-risk patients.
No statistically significant association emerged between prescription patterns and doctors' gender, specialisation or affiliation.
The pattern of preference among doctors interviewed by phone did not substantially differ from that of the responders: the only statistically significant difference was in the lower proportion of doctors prescribing tamoxifen in TjNo ER+ pre-menopausal patients (35% vs. 54%; P = 0.04).
Results of multivariate analyses
The logistical regression analysis applied to the premenopausal ER+ scenarios showed that physician age was an independent predictor of hormone treatment choice in TiN 0 patients. In fact, doctors older than 50 years were five times less likely to prescribe tamoxifen (OR = 5.1, 95% CI: 2.2-11.9) than those younger than 45. Physicians aged between 45 and 50 and those who had seen more than 300 breast cancer patients in the last year were also significantly less likely to prescribe tamoxifen (OR = 2.2, 95% CI: 1.1-4.5 and OR = 2.7, 95% CI: 1.3-5.4, respectively).
InT2No patients, responderage was the only predictor: doctors older than 50 years had a more than two-fold increased likelihood of not prescribing tamoxifen (OR = 2.4, 95% CI: 1.2-4.9) than those younger than 45.
As far as node-positive patients are concerned, treatment choice was related to physician affiliation. In fact, doctors participating in the GIVIO group were significantly more likely to prescribe tamoxifen than those sampled from the two scientific societies (OR = 0.5, 95% CI: 0.2-0.98).
Discussion
A recent international survey among medical opinion leaders on four continents [2] showed wide variation in the use of adjuvant tamoxifen, with substantial underuse in younger women and women with node-negative disease, among whom only half of the responders used the treatment.
Our study, involving a large sample of Italian physicians, reached similar conclusions. Less than half of the responders would routinely prescribe adjuvant hormone therapy in pre-menopausal ER+ women, irrespective of disease stage.
It is important to underline that the survey was started before the results of the last worldwide overview were published [1] and our result may reflect the residual uncertainty about the efficacy of tamoxifen in younger women, which had not been resolved before the previous meta-analysis, which showed no clear benefit in terms of overall survival in this subgroup [3] .
However, even among post-menopausal ER+ women, for whom the evidence of a substantial benefit was documented many years ago, about one-quarter of the responders would not routinely prescribe hormonal therapy. In contrast, more than one-third of responders would use tamoxifen in post-menopausal ER-negative patients. Again, this finding could reflect the previous overview [3] (not confirmed by the most recent one), suggesting a similar effect in oestrogen-positive and oestrogen-negative disease: with the availability of more reliable ER assays, the number of false-positive ER assays has been reduced and among women with reliably-tested ER-poor disease the size of benefit is much smaller.
As far as treatment duration is concerned, most of the physicians considered five years as standard. Nonetheless, one in four doctors prescribed tamoxifen for a shorter period of time in node-negative pre-menopausal women. In both pre-and post-menopausal women, a small proportion of responders used tamoxifen for more than five years. This variation in the prescribed length of tamoxifen use reflects the uncertainty concerning the optimal duration of hormonal treatment [4] . While the most recent overview confirms the greater benefit of five years of tamoxifen compared with shorter treatment regimens (at least for recurrence), the EBCTCG overview could not assess the effects of more than five years of adjuvant tamoxifen because there was, and is, too little reliable randomised supportive data. Large-scale randomised evidence is needed to address this question and trials are now ongoing with this as the primary objective.
Among physicians' characteristics, older age seemed to be an important predictor of tamoxifen underutilisation, particularly for lower-risk women. Fifty-eight percent of responders aged 50 years or more were head of their respective departments/wards and would thus influence treatment policies at the local level. From this point of view, the true utilisation of tamoxifen in clinical practice could be even lower than that reported in our survey. Along the same line, among non-responders interviewed by phone the proportion of physicians using tamoxifen in TiN 0 younger patients was significantly lower, suggesting that our data could have over-estimated the use of hormone treatment in pre-menopausal women.
No other physician characteristics consistently influenced their choices. The lower rate of tamoxifen prescription in low-risk pre-menopausal women among doctors seeing more than 300 breast cancer patients per year, though difficult to interpret, is consistent with that of previous reports [5] .
The general lack of association between physician affiliation and treatment preference (with the exception of N+ pre-menopausal patients) is rather disappointing. In fact, given the long tradition of participation in multicentre randomised trials on breast cancer treatment, we expected a higher rate of use of tamoxifen among GIVIO responders, but hope that the dissemination of the last EBCTCG overview will result in a wider and more appropriate readiness to use the drug in the large majority of women with early breast cancer who stand to benefit.
Finally, some of the potential limitations of our study need to be discussed. As a first point, the response rate of 50% could cast some doubt as to the representativeness of responders. Nevertheless, telephone interviews with one-quarter of the non-responders yielded the information that many of them did not see breast cancer patients. In addition, the opinions of the clinicians interviewed by phone did not substantially differ from those of the other responders.
It is also possible that the responders' opinions do not reflect the more general attitudes toward tamoxifen use. In fact, it is likely that physicians who answered the questionnaire were those more interested in the problem. The high percentage of doctors seeing more than 300 breast cancer patients per year seems to confirm this hypothesis. From this viewpoint, we can imagine that the underuse of tamoxifen is even more pronounced among clinicians practising in small centres and treating a wide range of different cancers.
Conclusions
Although tamoxifen is currently prescribed to more than one million women with breast cancer, it is likely that many women's lives are still lost each year because it is not being used optimally.
From the data of the recent overview [1] , an additional 20,000 lives each year could be saved worldwide if tamoxifen was given to all early breast cancer patients with hormone-sensitive disease, irrespective of age and disease stage, and for a minimum of five years.
The delay in incorporating new scientific evidence into clinical practice has often been described and the reasons underlying it are the subject of much debate [6] . Our data call for the devotion of intensive effort to the definition of meaningful guidelines to facilitate the adoption of emerging research evidence into routine practice. The need for standardisation of cancer practice through nationally accepted treatment guidelines has already been advocated as a fundamental tool to ensure the provision of quality medical care at adequate costs [7] [8] [9] . The experience of the National Comprehensive Cancer Network (NCCN) represents a valuable step in this direction [10] . The involvement of local opinion leaders in this process will represent a key factor in the facilitation of the necessary changes in therapeutic approach and thus help to improve the outcome of breast cancer patients.
In this respect, the periodical performance of physician surveys, together with clinical data audit [11] , can become an efficient tool for monitoring the knowledge of and adherence to widely accepted clinical recommendations.
